Novartis

Strategic intent

Novartis is a global innovative medicines company focused on researching, developing, manufacturing, and commercializing prescription pharmaceuticals across core therapeutic areas including oncology, immunology, cardiovascular-renal-metabolic, neuroscience, and rare diseases.

Key market signals

• 2026-10: Novartis presented positive Phase III REMODEL-1 and REMODEL-2 trial results for its oral multiple sclerosis drug remibrutinib, demonstrating superior relapse control over teriflunomide, though its stock fell due to lower efficacy compared to a rival Roche drug.
• 2026-10: Novartis received European Commission approval for Cosentyx (secukinumab) as the first interleukin-17A inhibitor for adults with polymyalgia rheumatica (PMR).
• 2026-10: Novartis entered into a licensing and option agreement with Abogen Biosciences worth up to $7.8 billion ($575 million upfront) to advance mRNA-encoded T-cell engager therapeutics, specifically lead asset ABO2203 for autoimmune diseases.
• 2026-09: Novartis suffered a major R&D setback when del-desiran, the centerpiece of its $12 billion acquisition of Avidity Biosciences, failed to meet its primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1.
• 2026-08: Novartis completed the acquisition of UK-based biotech Myricx Bio for up to $1.5 billion ($1.1 billion upfront), expanding its oncology pipeline with a novel N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate platform.

Financial health

• For the full year 2025, Novartis reported net sales of $54.53 billion, representing an 8% increase in constant currencies, and core operating income of $17.64 billion (https://www.novartis.com/news/media-releases/novartis-annual-results-2025).
• For Q2 2026, Novartis reported net sales of $14.41 billion, representing a 2.5% increase year-over-year, and net income of $3.26 billion (https://www.novartis.com/news/media-releases/novartis-q2-2026-results).

Impact & compliance

Legal & risks

In May 2026, the Superior Court of New Jersey revived a whistleblower retaliation lawsuit against Novartis by a former compliance advisor. In March 2026, a class-action lawsuit was filed in New Jersey alleging Novartis secretly installed tracking tools on its branded drug websites to share […]

Forensic audit — 3 findings

• ⚠ On July 21, 2026, the U.S. Court of Appeals for the District of Columbia Circuit affirmed a district court judgment in N...
• ⚠ On July 1, 2026, the U.S. Court of Appeals for the Eighth Circuit ruled in Novartis Pharmaceuticals Corp. v. Hanaway tha...
• ⚠ On May 17, 2026, the U.S. District Court for the Eastern District of Arkansas denied Novartis's request for a preliminar...

🔒 Proprietary analysis

Proprietary Analysis — available with full access

Want the full analysis?

Get access to strategic fit scoring, cultural fit analysis, full forensic detail, and alignment dimensions.